Artiva Biotherapeutics grants Elaine Sorg 13,750 options

Artiva Biotherapeutics granted director Elaine K. Sorg 13,750 stock options that vest by the 2027 annual stockholder meeting.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a grant of 13,750 director stock options on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036. According to the award terms, all shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. Following this grant, Sorg holds 13,750 options directly.

Insider Trade Summary

Grant/Award: 13,750 shares

Grant/Award 1 txn

Insider Sorg Elaine K.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	13,750	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Options granted: 13,750 options Exercise price: $10.88 per share Expiration date: September 7, 2036 +2 more

5 metrics

Options granted 13,750 options Director stock option grant to Elaine K. Sorg on September 8, 2026

Exercise price $10.88 per share Exercise price of director stock options granted September 8, 2026

Expiration date September 7, 2036 Expiration of the granted director stock options

Vesting trigger date September 8, 2027 or 2027 annual meeting Options vest in full on the earlier of these dates

Options held after transaction 13,750 options Total director stock options held directly by Elaine K. Sorg after grant

Key Terms

Director Stock Option, exercise price, vesting, annual stockholder meeting

4 terms

Director Stock Option financial

"Director Stock Option (Right to Buy)"

exercise price financial

"The options have an exercise price of $10.88 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option will vest in full on the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual stockholder meeting financial

"or the date of the Issuer's 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

What insider transaction did ARTV report for director Elaine K. Sorg?

Artiva Biotherapeutics, Inc. reported a grant of 13,750 director stock options to Elaine K. Sorg on September 8, 2026, as a compensation-related award, with no shares sold or purchased in the market.

What is the exercise price of the new stock options granted by ARTV?

The director stock options granted to Elaine K. Sorg have an exercise price of $10.88 per share, allowing her to buy Artiva Biotherapeutics, Inc. common stock at that price once the options vest and are exercised.

When do Elaine K. Sorg’s ARTV stock options vest?

All 13,750 options will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting, according to the award’s vesting terms.

When do the director stock options reported by ARTV expire?

The stock options granted to Elaine K. Sorg by Artiva Biotherapeutics, Inc. expire on September 7, 2036, giving her approximately ten years from the grant date to exercise the options, subject to the vesting conditions.

How many ARTV options does Elaine K. Sorg hold after this grant?

Following this reported transaction, Elaine K. Sorg directly holds 13,750 director stock options in Artiva Biotherapeutics, Inc., all stemming from this single grant reported on September 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:57 PM Accepted by SEC EDGAR 09/08/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sorg Elaine K.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.88	09/08/2026		A		13,750		(1)	09/07/2036	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)